Back to results
US 2017/0362200 A1Published application
Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
AssigneeTheravance Respiratory Compa, LLC
InventorsAdam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric L. STANGELAND, Richard D. WILSON, Rose YEN
Life of this patent
Estimating the term…
Abstract
This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
Claims4
1-35. (canceled)
A compound of the formula:
- wherein:.
- G2 is —NH2 or —COOH;
- Ar1 is selected from phen-1,3-ylene and phen-1,4-ylene, Wherein the phenylene group is unsubstituted or substituted with 1 to 3 substituents selected independently from C1-3 alkyl, —O—(C1-3 alkyl) and halo;
- R1 is selected independently from C1-3 alkyl, —O—(C1-3 alkyl), hydroxyl and halo;
- R2 is selected independently from C1-3 alkyl, —O—(C1-3 alkyl) and halo;
- R3 is selected independently from C1-3 alkyl;
- or two R3 groups are joined to form C1-3 alkylene, C2-3 alkenylene or oxiran-2,3-diyl;
- a is 0, 1, 2 or 3;
- b is 0, 1, 2 or 3;
- c is 0, 1, 2, 3 or 4;
- n is 0 or 1;
- p is 0, 1, 2, 3, 4, 5 or 6;
- provided that when n is 0, p is 1, 2, 4, 5 or 6;
- and
- Ra is selected from C1-6 alkyl.
12 more elements
Dependencies are inferred from the claim text.